A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study

BACKGROUND: A recent phase III trial did not confirm the previous clinical and endoscopic improvements seen in patients with Crohn’s disease (CD) receiving Mongersen, an oral Smad7 antisense oligonucleotide. Factors accounting for such a discrepancy are unknown. OBJECTIVE: Our objective was to furth...

Descripción completa

Detalles Bibliográficos
Autores principales: Marafini, Irene, Stolfi, Carmine, Troncone, Edoardo, Lolli, Elisabetta, Onali, Sara, Paoluzi, Omero Alessandro, Fantini, Massimo C., Biancone, Livia, Calabrese, Emma, Di Grazia, Antonio, Monteleone, Ivan, Lenti, Marco Vincenzo, Di Sabatino, Antonio, Monteleone, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084825/
https://www.ncbi.nlm.nih.gov/pubmed/33871807
http://dx.doi.org/10.1007/s40259-021-00482-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084825/
https://www.ncbi.nlm.nih.gov/pubmed/33871807
http://dx.doi.org/10.1007/s40259-021-00482-x

Ejemplares similares